10-Q: Cryomass Technologies Reports Q3 2024 Results, Revenue Growth Offset by Continued Losses

Cryomass Technologies Inc. reported a net loss of $1.1 million for the third quarter of 2024, despite a small increase in revenue and a decrease in operating expenses.

Summary

• Cryomass Technologies Inc. reported a net loss of $1.1 million for the three months ended September 30, 2024, compared to a net loss of $1.45 million for the same period in 2023.
• The company's revenue for the quarter was $5,000, a significant increase from zero revenue in the prior year's quarter.
• Operating expenses decreased by 37% to $870,859, primarily due to reduced personnel costs, general and administrative expenses, and legal and professional fees.
• For the nine months ended September 30, 2024, the company's net loss was $5.28 million, compared to a net loss of $9.41 million for the same period in 2023.
• Revenue for the nine-month period was $24,189, up from zero in the prior year.
• The company's operating expenses for the nine-month period decreased by 67% to $3.04 million, mainly due to a decrease in impairment charges, general and administrative costs, personnel costs, and depreciation and amortization expenses.
• Cryomass has a working capital deficit of $6.95 million and a cash balance of $183,439 as of September 30, 2024.
• The company estimates it needs $3.6 million to cover overhead costs and up to $2.7 million for capital expenditures over the next twelve months.
• Cryomass has a contingent royalty liability of $2.67 million related to a net revenue sharing agreement.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial losses, a working capital deficit, and going concern uncertainty. While there are some positive developments, such as revenue growth and reduced operating expenses, the overall outlook is negative due to the company's financial instability and internal control issues.

Positives

• The company's revenue increased to $5,000 in Q3 2024, compared to no revenue in the same period last year.
• Operating expenses decreased by 37% in Q3 2024, indicating improved cost management.
• The net loss for the nine months ended September 30, 2024, decreased by 44% compared to the same period in 2023.
• The company has secured agreements for the sale and lease of its CryoSift Separator units, although revenue recognition is deferred.

Negatives

• The company continues to operate at a loss, with a net loss of $1.1 million for Q3 2024 and $5.28 million for the nine months ended September 30, 2024.
• Cryomass has a significant working capital deficit of $6.95 million.
• The company's cash balance is low at $183,439 as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a contingent royalty liability of $2.67 million.
• The company terminated its agreement with RubberRock due to non-compliance, and is repossessing the CryoSift Separator.

Risks

• The company's ability to continue as a going concern is uncertain, depending on future revenue, debt, or equity investments.
• The company has a significant working capital deficit and low cash reserves.
• The company is reliant on securing additional financing to cover operating costs and capital expenditures.
• The company faces risks related to the implementation of its business model and the commercialization of its technology.
• The company's internal controls over financial reporting are not effective, which could lead to material misstatements in financial statements.
• The company is subject to risks related to the cannabis and cannabinoid industries, including regulatory changes and competition.

Future Outlook

The company expects to finance future cash needs from operations and additional financing until it achieves profitability and positive cash flows, but there is no assurance of this.

Management Comments

• Management believes that the company's available cash balance will not be sufficient to fund its anticipated level of operations for at least the next twelve months.
• Management believes that the company's ability to continue operations depends on cash from planned equipment sales and processing fees, or possibly from debt or equity investments.
• Management intends to develop or improve procedures to address the current significant deficiencies in internal controls.

Industry Context

The company operates in the cannabis and hemp industry, which is experiencing growth due to increasing acceptance of medicinal products and anticipated legislative changes. The company's technology aims to improve post-harvest methods and reduce costs for cultivators and processors.

Comparison to Industry Standards

• The company's revenue is minimal compared to established players in the cannabis and hemp processing industry.
• The company's significant losses and working capital deficit are concerning compared to industry benchmarks for companies at a similar stage.
• The company's reliance on external financing is a common challenge for early-stage companies in this sector, but the level of uncertainty is higher than average.
• The company's technology is innovative, but its commercial success is not yet proven, unlike companies with established market presence and revenue streams.
• The company's internal control deficiencies are a significant concern compared to industry standards for public companies.

Related Party Transactions

• The company has related party transactions with CRYM Co-Invest LP, including a loan agreement and warrant issuance.
• The company received loans from directors Simon Langelier, Health Diplomats Pte Ltd, and Mario Gobbo.
• The company received $80,000 related to a territory license fee from a related party.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or restructuring due to the company's financial challenges.
• Customers may experience delays or disruptions in the delivery of products and services due to the company's financial constraints.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to continue to evaluate and strengthen its internal control over financial reporting.
• Management intends to develop or improve procedures to address the current significant deficiencies to the extent possible during the next twelve months.
• The company will continue to work with an extensive pipeline of cultivators and processors in various markets.
• The company expects to deliver its first production commercial unit in the fourth quarter of 2024.

Key Dates

Keywords

Cryomass Technologies, cannabis, hemp, trichome separation, cryogenic processing, CryoSift Separator, financial results, revenue, net loss, operating expenses, going concern, internal controls, deferred revenue, related party transactions